With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
What effect does doubling the dose of clopidogrel have on outcomes in patients undergoing PCI? Dr. Salim Yusuf discusses the results of the CURRENT-OASIS 7 trial and other new data on antithrombotic agents.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.
AF can lead to stroke, congestive heart failure, and other serious complications. Successful management should include reducing these risks. Join our expert panel, Drs. Peter Rothwell, Donald Easton, and Mark Alberts, as they discuss new data and strategies for improving outcomes in patients with AF.
Despite modern therapy, the rates of death, MI, bleeding, and readmission remain high in patients with ACS. Join Drs. Jeffery Popma, Héctor Bueno, Freek Verheugt, and Sunil. Rao for a review of the latest data on antiplatelet therapy for patients with ACS.
How can we reduce the time taken to accurately diagnose ACS? ECGs and biomarkers may be nondiagnostic, even the presenting symptoms can vary or be absent. As every 30 minutes delay is associated with a 7.5% relative increase in mortality, time is indeed muscle. Join Drs. Gibson, Pride, Santini, and Krucoff as they present new insights into this complex field.
Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Drs. Keith Fox, Gregg Stone, and Gabriel Steg as they discuss balancing the safety and efficacy of antithrombotic treatment options in ACS.
Atrial fibrillation (AF) is the most frequently occurring cardiac arrhythmia affecting some 2.2 million Americans with often serious clinical consequences.. Join Drs. Bhatt, Connolly and Camm for a discussion on the risk factors, management challenges, and new data on treatment options for patients with AF
Although research has demonstrated the effectiveness of ICDs in preventing sudden cardiac death, many eligible patients still do not receive them. Join Drs. Prystowsky, Califf, Al-Khatib, Yancy, and Daniel in a lively discussion on how to eliminate these disparities.
The world's first MR-conditional pacemaker system designed for safe use in MRI represents a major milestone in the evolution of ICDs. Dr. Bruce Wilkoff from the Cleveland Clinic speaks on the significance of having this new technology available to patients.
Join Drs. Prystowsky, Lau, and Oseroff as they provide an international perspective on the prevention of sudden cardiac arrest in the Pacific Rim and South America.
Can genetic screening identify patients at increased risk for these cardiac events if left untreated? Join Dr Priori for a review of the current data on this rapidly evolving topic.
Framingham, Reynolds, CRP, calcium..? How best to assess CVD risk in women? Drs Redberg, Hayes, Lloyd-Jones, and Wenger discuss optimal risk stratification, the utility of preclinical screening and the importance of treating traditional risk factors in female patients.
Several recent studies have demonstrated that patients with atherothrombosis who experience bleeding may be at increased risk for long-term adverse ischemic events. Whereas the specific mechanism(s) that may explain the correlation between bleeding and ischemic events remains to be fully elucidated, these findings may have important ramifications for the selection of appropriate antiplatelet therapy. Drs. Berger, Mehta, Simon, Steg, and White discuss.
Harmonizing guideline recommendations for antiplatelet therapy with recent clinical trial data and concerns about bleeding can pose a challenge. Drs Berger, Mehta, Simon, Steg, and White each give presentations addressing issues relating to the appropriate use of antiplatelet therapy in patients with atherothrombotic disease
This program will examine the importance of acute and long-term dual antiplatelet therapy to protect ACS patients against thrombotic events. It will also provide information on established treatment guidelines and pivotal evidence-based clinical trial results arising from head-to-head comparisons of antiplatelet treatment options.
What is the prevalence and clinical impact of lead failure on the patient and their QOL? Our panel of experts, Drs Ellenbogen, Epstein, Wilkoff, and Auricchio discuss evidence-based strategies for managing this important issue.
Warfarin remains the cornerstone of stroke prevention in patients with AF. However, many patients are unable or unwilling to take it. Could antiplatelet therapy fill this gap? How might investigational anticoagulants change the playing field? Dr Naccarelli leads a panel discussion with Drs Connolly and Camm.
Data have shown that less than 40% of eligible patients hospitalized for heart failure received ICDs. Rates of use among women and black patients were significantly lower than among white men. Join Drs Fonarow, Hernandez, and Peterson in a lively discussion in how to overcome these disparities.
Depression is common in patients with CVD and is associated with poor outcomes. Drs Redberg, Hayes, Vaccarino and Wenger discuss the links between depression and CVD as well as ways to integrate screening and treatment of depression into your practice.
Underdiagnosed and undertreated, PAD is a growing health and economic burden in an increasingly aging population. Routine screening and effective management strategies can reduce long-term adverse outcomes. Join Drs Bhatt, Steg, Hirsch, and Hiatt as they discuss treatment guidelines for prevention and treatment of PAD.
This program discusses the optimal use of combination antiplatelet therapy in non-ST elevation ACS, both in the acute and long-term setting. Additionally, the program will touch upon the early use of combination antiplatelet therapy in the setting of STEMI. Referencing the recent joint statement on DES by the Canadian Association of Interventional Cardiologists and the Canadian Cardiovascular Society, the program will also discuss optimal duration of dual antiplatelet therapy, strategies to prevent early discontinuation, and potential management strategies for patients who may require surgery while on dual antiplatelet therapy.
What is the ideal antithrombotic therapy for the management of STEMI patients? Please join Dr Antman and an expert panel as they discuss the latest clinical trial data from the AHA 2006 Scientific Sessions regarding the management of STEMI patients.
What effect does doubling the dose of clopidogrel have on outcomes in patients undergoing PCI? Dr. Salim Yusuf discusses the results of the CURRENT-OASIS 7 trial and other new data on antithrombotic agents.
Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.
Although research has demonstrated the effectiveness of ICDs in preventing sudden cardiac death, many eligible patients still do not receive them. Join Drs. Prystowsky, Califf, Al-Khatib, Yancy, and Daniel in a lively discussion on how to eliminate these disparities.
Recent data among heart patients have suggested that approximately 2.3% of patients with a defected implant lead attached to their defibrillator will experience lead fracture within 30 months of having the device implanted. What are your thoughts and is this happening in your clinical practice?
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
How can we reduce the time taken to accurately diagnose ACS? ECGs and biomarkers may be nondiagnostic, even the presenting symptoms can vary or be absent. As every 30 minutes delay is associated with a 7.5% relative increase in mortality, time is indeed muscle. Join Drs. Gibson, Pride, Santini, and Krucoff as they present new insights into this complex field.